- In June 2023, The Lancetโsย eClinicalMedicineย journal published combined detailed analyses of Cleneโs Phase 2 RESCUE-ALS study and its open-label extension trial
- In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises
- As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets
- Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication
Clene (NASDAQ: CLNN)ย is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (โALSโ), Parkinsonโs disease, and multiple sclerosis (โMSโ).
Its lead drug candidate is CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience toโฆ
NOTE TO INVESTORS:ย The latest news and updates relating to CLNN are available in the companyโs newsroom atย https://ibn.fm/CLNN
About BioMedWire
BioMedWireย (โBMWโ) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, โBiotechโ to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visitย https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:ย https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered byย IBN
